Fenofibric acid
- Generic Name
- Fenofibric acid
- Brand Names
- Fibricor, Trilipix
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15ClO4
- CAS Number
- 42017-89-0
- Unique Ingredient Identifier
- BGF9MN2HU1
- Background
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol. Due to its high hydrophilicity and poor absorption ...
- Indication
For use as an adjunctive therapy to diet to: (a) reduce triglyceride levels in adult patients with severe hypertriglyceridemia, and (b) reduce elevated total cholesterol, low-density-lipoprotein (LDL-C), triglycerides, and apolipoprotein B, and to increase high-density-lipoprotein (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipide...
- Associated Conditions
- Hypertriglyceridemias, Mixed Dyslipidemias, Primary Hypercholesterolemia
- Associated Therapies
- -
To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT01501435
- Locations
- 🇰🇷
Yonsei university severance hospital, Seoul, Korea, Republic of
Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT
- Conditions
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 100
- Registration Number
- NCT01356290
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Piedmont Healthcare
- Target Recruit Count
- 18
- Registration Number
- NCT01030328
- Locations
- 🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
Study of Trilipix Effects on Lipids and Arteries
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 24
- Registration Number
- NCT01025492
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Mutual Pharmaceutical Company, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00960570
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.